The global food allergy treatment market size is anticipated to reach USD 11.12 billion by 2030 and is projected to grow at a CAGR of 9.44% from 2024 to 2030. Key factors propelling the market growth includes the rising prevalence of food allergies worldwide and increasing R&D activities for novel drugs. Moreover, the adoption of new biological agents to treat food allergies and an increase in clinic visits by patients seeking therapy for food allergies are likely to drive the market growth over the forecast period.
The increase in funding for allergy treatments is driving advancements in research, development, and accessibility of innovative therapies, addressing the growing demand for more effective treatments & management strategies. This heightened financial support is propelling market growth and fueling the development of safer and more accessible solutions for those affected by this condition. In September 2022, COUR Pharmaceuticals, a clinical-stage biotechnology company, completed a USD 30 million financing round, with Alpha Wave Ventures as the lead investor. This funding will support the expansion of COUR's innovative immune-modifying nanoparticles (COUR NanoParticles or CNPs) technology platform. Furthermore, it will facilitate the progression of the company's two human proof-of-concept studies focused on treating food allergies. This significant investment highlights the potential for advancing immune system reprogramming approaches to address autoimmune disorders and food allergies.
Novel drugs such as Xolair, and PALFORZIA boost the market growth. In January 2020, the FDA's approval of PALFORZIA marked a significant milestone in Food Allergy Treatment. PALFORZIA addresses a crucial unmet medical need by providing a treatment option for peanut allergies. Prior to its approval, patients had limited choices beyond strict avoidance, and this approval introduced a potentially life-changing solution. This oral immunotherapy product is specifically indicated for mitigating allergic reactions, including anaphylaxis that might occur from accidental peanut exposure in children aged 4 to 17 years with a confirmed diagnosis of peanut allergy. The FDA's requirement for a Risk Evaluation and Mitigation Strategy (REMS) ensures the safe and controlled administration of PALFORZIA, boosting patient safety and healthcare provider confidence. PALFORZIA, used alongside a peanut-avoidant diet, is tailored to meet the needs of patients while being contraindicated in cases of uncontrolled asthma and eosinophilic esophagitis and other eosinophilic gastrointestinal diseases, further emphasizing its safety and suitability for specific patient populations.
However, Nestlé's Palforzia faced significant challenges. Despite a substantial investment of USD 2.6 billion in its development, the treatment regimen proved to be too cumbersome for many potential patients. When Palforzia entered the market in 2020, physicians were initially excited to offer it to their patients. However, the COVID-19 pandemic disrupted in-person treatment plans. As a result, doctors resorted to informing approximately 1,000 patients about the new drug as an option for postpandemic use. Surprisingly, only six individuals expressed interest in the treatment that had been heralded as an efficient solution for life-threatening peanut allergy, having received clearance from U.S. authorities. Even after three years, many physicians have not prescribed Palforzia. Across the U.S., it appears that doctors & patients are opting for the traditional approach of avoiding allergens and carrying adrenaline injections for emergencies instead. As a significant development in the market, in September 2023, Nestlé divested its Palforzia business to Stallergenes Greer, a company specifying in allergy diagnosis and treatment. This strategic move followed Nestlé's earlier announcement of a review of Palforzia, with Nestlé set to receive milestone payments and ongoing royalties as part of the agreement.
The increase in funding for allergy treatments is driving advancements in research, development, and accessibility of innovative therapies, addressing the growing demand for more effective treatments & management strategies. This heightened financial support is propelling market growth and fueling the development of safer and more accessible solutions for those affected by this condition. In September 2022, COUR Pharmaceuticals, a clinical-stage biotechnology company, completed a USD 30 million financing round, with Alpha Wave Ventures as the lead investor. This funding will support the expansion of COUR's innovative immune-modifying nanoparticles (COUR NanoParticles or CNPs) technology platform. Furthermore, it will facilitate the progression of the company's two human proof-of-concept studies focused on treating food allergies. This significant investment highlights the potential for advancing immune system reprogramming approaches to address autoimmune disorders and food allergies.
Novel drugs such as Xolair, and PALFORZIA boost the market growth. In January 2020, the FDA's approval of PALFORZIA marked a significant milestone in Food Allergy Treatment. PALFORZIA addresses a crucial unmet medical need by providing a treatment option for peanut allergies. Prior to its approval, patients had limited choices beyond strict avoidance, and this approval introduced a potentially life-changing solution. This oral immunotherapy product is specifically indicated for mitigating allergic reactions, including anaphylaxis that might occur from accidental peanut exposure in children aged 4 to 17 years with a confirmed diagnosis of peanut allergy. The FDA's requirement for a Risk Evaluation and Mitigation Strategy (REMS) ensures the safe and controlled administration of PALFORZIA, boosting patient safety and healthcare provider confidence. PALFORZIA, used alongside a peanut-avoidant diet, is tailored to meet the needs of patients while being contraindicated in cases of uncontrolled asthma and eosinophilic esophagitis and other eosinophilic gastrointestinal diseases, further emphasizing its safety and suitability for specific patient populations.
However, Nestlé's Palforzia faced significant challenges. Despite a substantial investment of USD 2.6 billion in its development, the treatment regimen proved to be too cumbersome for many potential patients. When Palforzia entered the market in 2020, physicians were initially excited to offer it to their patients. However, the COVID-19 pandemic disrupted in-person treatment plans. As a result, doctors resorted to informing approximately 1,000 patients about the new drug as an option for postpandemic use. Surprisingly, only six individuals expressed interest in the treatment that had been heralded as an efficient solution for life-threatening peanut allergy, having received clearance from U.S. authorities. Even after three years, many physicians have not prescribed Palforzia. Across the U.S., it appears that doctors & patients are opting for the traditional approach of avoiding allergens and carrying adrenaline injections for emergencies instead. As a significant development in the market, in September 2023, Nestlé divested its Palforzia business to Stallergenes Greer, a company specifying in allergy diagnosis and treatment. This strategic move followed Nestlé's earlier announcement of a review of Palforzia, with Nestlé set to receive milestone payments and ongoing royalties as part of the agreement.
Food Allergy Treatment Market Report Highlights
- By allergen type, the peanuts segment led the market with the largest revenue share of 26.62% in 2023. Key factors propelling market growth include, rising prevalence of peanut allergies worldwide and increasing R&D activities for novel drugs. Moreover, growing adoption of new biological agents to treat allergies and an increase in clinic visits by patients seeking therapy for this allergy are likely to drive the market growth over the forecast period
- Based on drug type, the epinephrine segment led the market with the largest revenue share of 18.17% in 2023. Epinephrine is considered to be the medication of choice for treatment of allergic conditions. Owing to its use as the initial treatment of choice for emergency allergic conditions
- By route of administration, the oral segment is projected to grow at the fastest CAGR of 10.14% over the forecast period. Oral food allergy treatment primarily employs Oral Immunotherapy (OIT), involving the gradual consumption of controlled amounts of food allergen
- By end use, the hospital pharmacies segment held the market with the largest revenue share of 40.18% in 2023. Hospital pharmacies serve as a critical distribution channel, facilitating the availability and efficient dispensation of medications and treatments essential for managing food allergies within a hospital environment
- North America dominated the market with the revenue share of 36.44% in 2023. The region held a major market share due to an increase in understanding of the high potential associated with allergy drugs
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Food Allergy Treatment Market Variables, Trends & Scope
Chapter 4. Food Allergy Treatment Market: Allergen Estimates & Trend Analysis
Chapter 5. Food Allergy Treatment Market: Drug Type Estimates & Trend Analysis
Chapter 6. Food Allergy Treatment Market: Route of Administration Estimates & Trend Analysis
Chapter 7. Food Allergy Treatment Market: End-use Estimates & Trend Analysis
Chapter 8. Food Allergy Treatment Market: Regional Estimates & Trend Analysis by
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Sanofi SA
- Aimmune Therapeutics
- DBV Technologies
- Vedanta Biosciences, Inc.
- Alladapt Immunotherapeutic, Inc.
- COUR Pharmaceuticals
- Aravax
- Prota Therapeutics
- Teva Pharmaceuticals
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | May 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 5.87 Billion |
| Forecasted Market Value ( USD | $ 11.12 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
